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Celiac disease is a common autoimmune disease triggered by gluten-containing foods (wheat, barley and rye) in
genetically predisposed individuals. We present a patient with celiac disease complicated by severe aphthous
stomatitis resulting in impairing swallowing, chewing and speaking. This led to weight loss, psychosocial problems
as well as inability to perform her work. A variety of topical and systemic medications used resulted in either no
improvement or only partial alleviation of the patient’s symptoms. After informed consent, etanercept was initiated
and resulted in complete remission of aphthous stomatitis, decrease in arthralgia and fatigue and considerable
improvement in her quality of life. The use of newer biological agents for selected and severe manifestations of
celiac disease may lead to improved morbidity in these patients, but more studies are needed to determine
long-term efficacy as well as safety of these drugs in the mucosal and/or systemic complications of this disease.
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Celiac disease (CD) is a common autoimmune disease.
The prevalence of CD is approximately 0.5% to 1% among
people living in the United States [1] and 1:100 to 1:300
worldwide [2]. It is more common in Caucasians and
affects both children and adults, with a female predom-
inance [1]. CD- otherwise known as Gluten-sensitive
enteropathy- is triggered by gluten-containing foods (wheat,
barley and rye) in genetically predisposed individuals and
can also be associated with other immunological diseases
such as diabetes mellitus type 1 and IgA deficiency, suggest-
ing immune dysregulation. Although patients are often
asymptomatic, CD can manifest with cutaneous, mucosal,
systemic or autoimmune features [3,4]. A variety of oral
lesions such as atrophic glossitis and aphthous ulcers
are quite common in patients with CD with A prevalence
ranging from 3% to 61% in several studies. Aphthous
stomatitis can be quite severe in CD, at time interfering
with chewing, swallowing, speaking, and leading to
impaired quality of life. This can result in complications* Correspondence: krishnas@etsu.edu
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reproduction in any medium, provided the orsuch as weight loss, nutrition deficiencies, depression and
psychosocial withdrawal.
We present a patient with severe aphthous stomatitis
complicating CD who responded partially to immune
suppression, but dramatically to the inhibitor of tumor
necrosis factor alpha (TNFα) - Etanercept. This report
suggests a role for cytokines such as TNFα in CD, and
also provides a potential treatment strategy for selected
mucosal complications associated with the disease.Case report
A 32 year old Caucasian female with a history of endo-
metriosis and fibrocystic breast disease presented with
severe ulcers of the mouth extending into the posterior
oropharynx. The presence of the ulcers was associated
with severe pain with difficulty eating, chewing or swal-
lowing, and interfered with her speech and quality of
life. The lesions appeared initially as blisters and were
followed by ulceration. These appeared in clusters over
weeks or months leading to severe disability. Periodically,
the patient would develop conjunctival injection, arthral-
gias and severe fatigue associated with the ulcers. A
thorough ophthalmological evaluation was negative for
glaucoma, cataracts, uveitis or scleritis.
The past medical history included allergic rhinitis
complicated by recurrent sinusitis. She also complainedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fingers, consistent with Raynaud’s phenomenon. The
patient’s medications included fexofenadine, montelukast
sodium, intranasal steroids, tryptan for migraine and
sertraline. A recent gynecological examination was
unremarkable. Her family history was significant for a
first cousin with systemic lupus erythematosus (SLE).
Physical examination revealed multiple large aphthous
ulcers with involvement of the buccal mucosae, tongue
and palate (Figure 1A and B). A few lymph nodes in
the upper neck were slightly enlarged. Raynaud’s
phenomenon and livedoid changes were seen in the
upper extremities.
A thorough evaluation demonstrated normal liver func-
tion tests, low levels of Vitamin D, ferritin (19 ng/ml) and
thiamine (52 ng/ml) with normal levels of B12 and red
blood cell folate (Table 1). Tests for autoantibodies and
anti-cardiolipin antibodies were negative. Evaluation for
CD demonstrated significantly elevated levels of endo-
mysial and tissue transglutaminase (TTG) antibodies
(Table 2). Biopsies of the esophagus demonstrated typicalA B
C D
Figure 1 Images of physical examination findings and biopsy results.
aphthous ulcers and erythema. (A) A large, painful white ulcer with surroun
large, shaggy, inflamed ulceration of the lower lip. Granulation tissue, scarri
mucosa. (C & D) Ileal biopsy revealed villous blunting, crypt elongation, inc
intraepithelial lymphocytes (C-low power, D-high power).reflux changes, while biopsies of the ileum showed villous
blunting, mononuclear and T cell infiltration of the lamina
propria and epithelial loss (Figure 1C and D), confirming
the diagnosis of CD. Genetic evaluation and HLA-DQ typ-
ing demonstrated the presence of celiac disease permissive
alleles DQ alpha 1 0103, 0501 and DQ beta 1 0201, 0603,
further clinching the diagnosis. These results are summa-
rized in (Table 2), colonoscopy and biopsy were negative
for Inflammatory bowel disease. Biopsy of oral lesion did
not reveal vasculitis or Behcets syndrome.
Tetracycline swish and swallow as well as topical lido-
caine for the ulcers were initially prescribed. Replacement
with Vitamin D, thiamine and iron were initiated and
the patient was instructed to follow a strict gluten-free
diet. Reflux symptoms were also treated with a proton
pump inhibitor. The oral ulcers showed no response to
tetracycline and lidocaine but a partial response to sys-
temic glucocorticoids was seen, with relapse of symptoms
soon after discontinuation. A repeat endoscopy showed
normalization of the villous architecture in response to
treatment; however, the aphthous ulcers persisted unabated.A-D: Gross examination of the oral mucosa demonstrated multiple
ding erythema located on the soft palate is present. (B) Demonstrates
ng and ulceration were also observed on biopsy of the lower labial
reased inflammation in the lamina propria, and increased
Table 1 Other laboratory test results on patient
Name Result Normal value Comments
Anti-nuclear Ab (U/ml) 46 0-100 Normal
Anti-SSA Ab (U/ml) 44 0-100 Normal
Anti-SSB Ab (U/ml) 7 0-100 Normal
Cardiolipin IgG (GPL) 7 <15 Normal
Cardiolipin IgM (MPL) 8 <12 Normal
Cardiolipin Ab IgA (APL) 2 <12 Normal
Rheumatoid factor (IU/ml) <5 0-10 Normal
Anti-CCP Ab (Units) 3 <20 Normal
C3 complement (mg/dL) 119 89-187 Normal
C4 complement (mg/dL) 46.3 16.5-38.0 Increased-acute phase
Ig A (mg/dL) 82 66-436 Normal
Vitamin B1 (nmol/L) 52 70-180 Low
Ferritin (ng/mL) 19 6-159 Fe deficiency
Vitamin B12 (pg/mL) 425 193-982 Normal
RBC folate (ng/mL) 486 280-903 Normal
TSH (IU/ml) 2.28 0.4-4.0 Normal
WBC (K/microL) 4.4 4.8-10.8 Mild leukopenia
Hgb (g/dL) 11.4 12.0-16.0 Decreased; anemia
GPL = IgG phospholipid units; MPL = IgM phospholipid units; APL = IgA phospholipid units; CCP = cyclic citrullinated peptide; pg/Ml = Picograms/milliliter;
RBC = Red Blood Cell; TSH = Thyroid Stimulating Hormone; WBC =White Blood Cell; Hgb = Hemoglobin.
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narcotics for pain. A lip biopsy was performed and
demonstrated mucositis and granulation tissue. Fungal
stains and PCR for herpes simplex virus were negative.
The patient was started on and failed hydroxychloro-
quine, sucralfate, cyclosporine, azathioprine and colchicine.
After informed consent and insurance approval, the patient
was started on etanercept at a dose of 25 mg biweekly
administered subcutaneously, after an initial negative
tuberculin skin test. After adequate instruction, the patient
was able to comfortably self-administer the medication.
Pulmicort® Respules were prescribed for minor flares.
After Etanercept was initiated, the patient had complete
remission of the oral ulcers. She has also had dramaticTable 2 Diagnostic immunological test results
Test Result Normal value
Gliadin IgG Ab (Units) 69 <19 negative;
Gliadin IgA Ab (Units) 11 <19
Transglutaminase IgA Ab (Units) 72 0-19
Tissue transglutaminase IgG antibody (Units) 5 <20
Endomysial antibody titer 1:40 <1:10
DQ alpha 1 (MHR) 0103,0501
DQ beta 1 (MHR) 0201,0603
IgG Ab = Immunoglobulin G Antibodies; IgA Ab = Immunoglobulin A Antibodies; MHimprovements in the inflammatory symptoms including
conjunctival inflammation, polyarthralgia and fatigue.
Discussion
Celiac disease and its manifestation
Celiac disease is a chronic inflammatory, autoimmune
disorder of the small intestine with local and systemic
manifestations (Figure 2) [5-7]. The latter include mucosal
disease (dental/enamel hypoplasia, malabsorption syndrome,
aphthous stomatitis), dermatitis herpetiformis, osteopenia/
osteoporosis, nutritional issues such as short stature and
malnutrition with hypovitaminoses, infertility and delayed
puberty, seizures and/or ataxia, depression and auto-
immune endocrinopathy [5-7].Comments
19–31 weak positive; >31 positive Positive suggestive of celiac disease
Normal
Increased suggestive of celiac disease
Normal






Figure 2 Celiac disease and its complications/associations.
Figure 3 Immunopathogenesis of celiac disease and possible point of action of etanercept.
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logical factors and environmental factors in genetically
susceptible population, through activation of both cell-
mediated and humoral immune mechanisms [3,5-7]. After
ingestion of dietary sources of gluten (wheat, barley
and rye), gluten peptides, modified deamidated by tissue
transglutaminases expressed in the lamina propria of
the small intestines, are presented by professional antigen
presenting cells to gluten-specific CD4 T cells in lamina
propria of the intestinal cells and oral mucosa, in the
context of class II HLA molecules (DQ2 and 8). Gliadin-
reactive T cells in turn likely express interferon gamma
(IFNγ), a T helper type 1 cytokine, which in turn activates
metalloproteinases, resulting in some manifestations
of the disease. It is also likely that IFNγ enhances the
production of TNFα which may play a major role in
recruitment of lymphocytes and mucosal damage [8].
Possible sequence of events and the point of action of
Etanercept are shown in cartoon format in (Figure 3).
Of relevance to the patient discussed in this report,
Recurrent Aphthous Ulcers (RAU) have been reported
in patients with celiac disease, with variable frequencies
[9-11]. Some studies have shown no higher frequency of
RAU in CD compared to controls while others have
demonstrated more frequent occurrence. Cell mediatedTable 3 Systemic medications which have been used for treat
Medication Number
Pentoxifylline 400 mg TID 26 peop
14 patien
12 contr
Doxycyline 20 mg BID 50 patien
Zinc sulfate 150 mg BID 45 patien
Cholchicine (1–2) mg BID 169 patie
Clofazimine 100 mg QD For 1 month 23 patien
Prednisone up to 25 mg 60 patien
Montelukast 10 mg QD 60 patien
Thalidomide 50 mg QD 200 mg QD for HIV patients 20 HIV p
Chlorambucil 0.1 mg/kg Single ca
Infliximab 5 mg/kg QD Single ca
Etanercept 25 mg BiWeekly 40 patien
Levamisole 9 patientimmunity and/or formation of immune complexes may
play a part in RAU development in patients with CD,
though the actual mechanisms are unclear. Studies from
peripheral blood in otherwise healthy patients with RAU,
showed multiple immune system abnormalities. These
abnormalities included: depressed or reversed CD4:CD8
cell ratio (especially in patients demonstrating severe
aphthous stomatitis), increased γδ receptor-positive T cells
in patients with active RAU compared to controls, and
increased TNFα production [12]. In one study, patients
with RAU had elevated salivary levels of TNFα compared
to controls [13]. Increased numbers of γδ + cells suggest
an antibody-dependent cell-mediated cytotoxicity in
RAU pathogenesis. These specific T cells probably produce
TNF-α, a major mediator responsible for the initiation
of the inflammatory response through its effects on
endothelial cell adhesion and neutrophil chemotaxis.
Other inflammatory changes found in RAU lesions
include elevated IL-2 and IL-6, potentially due to local
tissue trauma. IL-2 can activate natural killer (NK)
cells. Increased activity of these cells has been seen in
active lesions, which also seems to diminish during re-
mission. These inflammatory mediators may also have
been responsible for the nonspecific symptoms suffered
by the patient.ment of RAU
of patients Results/outcome Reference
le ↓ ulcer size [14]
ts ↓ ulcers number
ol
ts ↑ remission [15]
↓ pain
ts ↓ ulcer size [16]
↓ symptoms
nts ↓ ulcer number [17]
↓ disease duration
ts ↓ ulcers number [18]
↓ disease duration
In 44%
ts ↓ ulcers number [19]
Faster healing
ts ↓ ulcers number [20]
Faster healing
atients Induce remission [21]
In HIV patients
se report Remission [22]
se report Remission [23]
ts ↓ ulcers number [24]
s ↓ ulcers number [25]
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biological response modifiers
Based on the immunological changes observed in RAU,
biological response modifiers have been attempted by
various physicians and researchers in an attempt to ameli-
orate or induce remission in severe disease. Systemic
medications reported in the literature include pentoxifyl-
line [14], doxycyline [15], Zinc Sulfate [16], Colchicine
[17], clofazimine [18], prednisone [19], montelukast sodium
[19], sulfones [20], thalidomide [21], methotrexate [22],
cyclosporin, chlorambucil [23], infliximab [24], etanercept
[25], interferon α [26], azathioprine [25] and levamisole
[27] (Table 3).
Recent advances in understanding of molecular inflam-
matory mechanisms have led to new treatments for inflam-
matory disease- including tumour necrosis factor-alpha
antagonists, infliximab, etanercept and adalimumab and
the T-cell modulator modifiers efalizumab and alefacept
[28]. Since recent studies have demonstrated a role for the
newer TNFα inhibitors in RAS [29-31], this intervention
was initiated in the patient, after informed consent.
In small case clusters or isolated reports, inhibition of
TNFα has been shown to alleviate aphthous stomatitis.
In one study, Infliximab, a chimeric anti-TNFα antibody,
administered intravenously was quite effective in managing
recurrent or refractory oral and genital ulcers, with no
evidence of recurrence [24]. In another study, Etanercept,
a fusion protein of the TNF-α receptor and the Fc portion
of human IgG1, had a favorable effect on RAS of the oral
cavity. In one review, sixteen patients underwent treat-
ment for refractory or severe aphthous ulcers with
tumor necrosis factor alpha antagonists, between 1995
and 2010 [32]. Of the drugs used, infliximab, etanercept
and adalimumab appeared to improve outcomes [32].
Sanchez-Cano et al., also reported improved outcomes
with adalimumab in a patients with severe aphthous
ulcers [33]. The role of cytokines such as TNFα in severe
aphthous stomatitis, especially in underlying disorders
such as CD needs to be clarified.
Approved uses for etanercept include treatment of
rheumatoid arthritis, juvenile rheumatoid arthritis, psori-
atic arthritis, plaque psoriasis and ankylosing spondylitis.
Recently this drug has also been utilized to treat complica-
tions in patients with HIV infection [34]. Off-label use has
extended to include Behcet’s disease, recurrent aphthous
stomatitis, pemphigoid and lichen planus [29]. A study
done by Pepple K. et al., showed that etanercept was used
for treatment of Alzheimer disease with small significant
improvement [35]. Another study done by Zalevsky et al.,
showed that the use of etanercept in HIV/AIDS does
not increase morbidity or mortality; in contrast it may
improve associated aphthous stomatitis, fatigue and
dementia [36]. As with any other immunosuppressant,
etanercept increases the risk of infections, lupus, systemicsclerosis and congestive heart failure. Etanercept may also
increase risk of lymphoma, central nervous system disease
such as multiple sclerosis, vasculitis and autoimmune
hepatitis but in clinical trials appears to have a favorable
risk-benefit ratio [37-39]. In the patient mentioned in this
report, dramatic improvement in mucosal disease as well
as in the systemic complications of fatigue an arthralgia
was convincing enough to allow her to stay on etanercept,
though the long term safety and efficacy are unknown and
need to be evaluated before firm recommendations on
such use could be recommended.
Conclusion
This patient had severe aphthous stomatitis complicating
CD, impairing swallowing, chewing and speaking. This
led to weight loss, psychosocial issues as well as inability
to perform her work. A variety of topical and systemic
medications used resulted in either no improvement or
only partial alleviation of her symptoms. The use of eta-
nercept resulted in remission of aphthous stomatitis and
considerable improvement of quality of life. The use of
newer biological for selected and severe manifestations of
CD may lead to improved morbidity in these patients, but
more studies are indicated.
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